GSK: Benlysta designated orphan drug by FDA

(CercleFinance.com) - Alongside its quarterly results, GSK announced on Wednesday that the US FDA has granted orphan drug designation to Benlysta for the treatment of systemic sclerosis.


Benlysta, a monoclonal antibody that inhibits B-cell activation, is scheduled to enter a Phase II/III clinical trial for the treatment of systemic sclerosis in the first half of 2023.

This is a systemic connective tissue disease characterised by microvascular involvement and can affect the heart, lungs, kidneys and skin.


Copyright (c) 2023 CercleFinance.com. All rights reserved.